Kris Orlowski
Family · Tacoma, WANPI 1609409085
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Novo Nordisk at 25.0% of the total. Reporting peaked in 2021 at $573 and has fallen 78.2% since, to $125 in 2025.
Across 99 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$478
- Vanda Pharmaceuticals Inc.$276
- Lilly USA, LLC$219
- AbbVie$185
- Pfizer$149
- Mayne Pharma Commercial LLC$142
- plus $464 from 12 others
What the payments were for
- Food & beverage$1,914100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $478 |
| Vanda Pharmaceuticals Inc. | 14 | $276 |
| Lilly USA, LLC | 10 | $219 |
| AbbVie | 9 | $185 |
| Pfizer | 7 | $149 |
| Mayne Pharma Commercial LLC | 8 | $142 |
| Medtronic | 3 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Antares Pharma, Inc. | 3 | $63 |
| Amarin Pharma, Inc. | 3 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| IBSA Pharma Inc. | 2 | $28 |
| Avion Pharmaceuticals | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Tempus AI, Inc | 1 | $19 |
How this compares
$1,914 in reported general payments places this provider in the 85th percentile of 1,706 family providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 12 | $77 |
Paid to pharmacies, not to this prescriber.
Other family in Tacoma
- Nasla LoyaTacoma$10K
- Tammi HudspethTacoma$8K
- Michelle HendrickxTacoma$7K
- Simon KatumuTacoma$6K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.